Over the next five years, many top-selling cancer drugs from major pharmaceutical companies will lose their patent protection. This is called a ‘patent cliff,’ and it could lead to big drops in revenue and other challenges for these companies. In the mid-2010s, many new cancer treatments, especially immune therapies and targeted drugs, were approved quickly. These drugs were granted special fast-track approvals, which meant they came to market sooner but also meant their patent protection would expire around the same time. When patents expire, generic or biosimilar versions of these drugs can enter the market, leading to big revenue losses—sometimes over 50% within two years. Companies that rely heavily on a few cancer drugs are at the highest risk. Past examples like Avastin, Gleevec, and Revlimid show how quickly sales can drop when cheaper alternatives become available. Companies that didn’t prepare for this lost market share and struggled to develop new treatments. However, some companies with strong pipelines or smart business strategies were able to handle the transition better. Now, drugs like Keytruda, Opdivo, and Darzalex are approaching patent expiration, putting billions of dollars in revenue at risk. Some companies have planned ahead with new treatments in development, while others are still at risk. To see which companies are ready, we looked at two key factors: how much they depend on soon-to-expire drugs and how strong their new drug pipelines are. We also measured how much money they stand to lose. Companies that are well-prepared, like Genentech (Roche), have strong pipelines and multiple treatments in development. Others, like Astellas, have fewer new treatments in the works and face bigger risks. MSD (Merck) has a strong pipeline but relies heavily on Keytruda, so they are working hard to develop new treatments to make up for the loss. To succeed, companies need to act now. They should focus on developing new treatments, speed up clinical trials, and look for partnerships or acquisitions to strengthen their pipelines. The patent cliff is coming, but companies can still take steps to protect themselves and come out stronger. At Intelligencia AI, we help pharmaceutical companies make smart decisions using data and AI to prepare for these challenges.